BRLS
Borealis Foods Gets Nasdaq Deficiency Notice Over Late Q2 10-Q
Borealis Foods says a review of the accounting treatment of its Conversion Agreement delayed its second-quarter report, triggering a Nasdaq compliance notice.
William Hayes
Clinical
Spectrum Pharmaceuticals Suspends Phase 3 Poziotinib Trial in HER2 NSCLC
The registry entry for the poziotinib study in HER2 exon 20-mutated lung cancer now reads SUSPENDED, with no patients enrolled and a redesign under discussion with the FDA.
HRMY
Harmony Biosciences Completes Phase 3 Cannabidiol Trial in Fragile X
The registry entry for Harmony's Phase 3 study of cannabidiol in Fragile X syndrome now shows a status of COMPLETED, updated 1 September 2026.
Clinical
PDS Biotechnology Terminates Phase 3 Trial of PDS0101 in HPV16+ Head and Neck Cancer
PDS Biotechnology has terminated its Phase 3 study of PDS0101 plus pembrolizumab, citing financial constraints rather than safety concerns.
VRT
Vertiv Signs $1.45 Billion Merger Deal for Utility Innovation Holdings
Vertiv Corporation agreed to acquire Utility Innovation Holdings via merger, with a base purchase price of $1.45 billion plus an earnout, per an 8-K filing.
INCY
Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed
The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.